【深圳商报讯】（记者 范宏韬）近日，华南（香港）国际仲裁院（英文简称SCIAHK）受理并办结一宗 港资企业作为当事人、仲裁地为香港的仲裁案件。据悉，该案为今年2月最高人民法院发布《最高人民 法院关于在粤港澳大湾区内地登记设立的香港、澳门投资企业协议选择港澳法律为合同适用法律或者协 议约定港澳为仲裁地效力问题的批复》以来，华南（香港）国际仲裁院受理的首例"港资港仲裁"案件。 2019年，经国务院港澳办批准，华南（香港）国际仲裁院由深圳国际仲裁院（又称"华南国际经济贸易 仲裁委员会"和"粤港澳大湾区国际仲裁中心"，英文简称SCIA）设立于香港，是内地机构在内地法域之 外设立的首家独立仲裁机构。自成立以来，华南（香港）国际仲裁院共办理54宗仲裁案件，经当事人明 确的案涉争议金额超过人民币27.7亿元。 记者了解到，本次由华南（香港）国际仲裁院管理的首宗"港资港仲裁"案件当事人分别为在深圳设立的 港资企业以及内地自然人，仲裁地为香港，开庭地点为深圳，仲裁员来自深圳国际仲裁院与华南（香 港）国际仲裁院"双城两院"仲裁员名册，案件审理实体法适用中华人民共和国法律，充分体现"双城、 双院、双法域、双法系、双规则、双名册"的 ...

Core Viewpoint - Shenzhen is leveraging international arbitration to enhance cross-border legal services and establish itself as a key player in the Guangdong-Hong Kong-Macao Greater Bay Area, thereby increasing the international credibility of Chinese arbitration [1][5]. Group 1: Development of Arbitration Mechanisms - Shenzhen International Arbitration Center (SCIA) has been authorized to implement comprehensive reform pilot tasks, aiming to create a new mechanism for cross-border arbitration cooperation [1]. - The SCIA has seen arbitration case amounts exceed 100 billion yuan for three consecutive years, positioning it among the world's leading arbitration institutions [1][5]. - The Guangdong Provincial People's Congress has encouraged courts to support arbitration institutions through investigation orders, marking a significant innovation in arbitration practices [2]. Group 2: International Collaboration and Expansion - SCIA has been recognized as one of the most popular arbitration venues globally, reflecting its transition from learning international rules to contributing Chinese solutions [3]. - The center has expanded its international partnerships, including collaborations with the Silicon Valley Arbitration and Mediation Center and the Asian International Arbitration Centre in Malaysia [3]. - SCIA has established representative offices in Xinjiang to facilitate dispute resolution for Chinese enterprises engaging in the Belt and Road Initiative [3]. Group 3: Digital Transformation in Arbitration - SCIA is advancing digitalization in arbitration, achieving 100% remote electronic filing by 2024 [4]. - The establishment of a smart arbitration department aims to enhance transparency and efficiency in dispute resolution [4]. - The center has implemented innovative technologies, such as AI, to improve the arbitration process, generating over 180,000 bilingual arbitration documents [5].

2025年6月23日，由北京仲裁委员会/北京国际仲裁院（以下称"北仲"）与伦敦国际仲裁院（London Court of International Arbitration，以下称"LCIA"）、英 国皇家特许仲裁员协会（Chartered Institute of Arbitrators，以下称"Ciarb"）、伦敦玛丽女王大学商法研究中心（Centre for Commercial Law Studies, Queen Mary University of London ，以下称"CCLS"）联合主办的"伦敦·2025中国商事争议解决高峰论坛"（以下称"高峰论坛"）在英国伦敦成功举办。 本次高峰论坛共有来自中国、英国、法国、加拿大、意大利、澳大利亚、斯洛文尼亚、黎巴嫩等不同国家和地区的34位发言嘉宾参与，吸引了包括仲裁 员、律师、仲裁从业者、学者、专家和高校学生等逾百名法律专业人士线下参会。 会议致辞 北仲主任郭卫、LCIA主任Kevin Nash、Ciarb董事会副主席Ben Giaretta、CCLS国际仲裁学院教授Loukas Mistelis出席论坛开幕式并致辞。北仲副秘书长陈 福勇主持。 郭卫在 ...

昨天（5月19日），在苏州市工商联和苏州市司法局联合举办的"积极应对贸易挑战 仲裁护航民企 发展"主题活动上，《苏州仲裁护航民营企业高质量发展的八项举措》发布，以创新仲裁机制优化营商 环境，为民营企业健康发展提供法治保障。 此次发布的八项举措涵盖多个方面，全方位保障民企权益。在深化仲裁联系民企制度方面，全市司 法行政系统、仲裁机构将加强与市工商联等部门的协作，借助商会仲裁联系点，组建工作小组走访民 企，了解需求，推广仲裁条款示范文本，提升服务质效。 为降低民企维权成本，苏州利用位于苏州工业园区的国际商事仲裁服务中心，采用视频连线等技 术，方便企业参加远程庭审；对困难企业给予缓、减、免交仲裁费优惠。开通"仲裁惠企"绿色通道，推 动服务标准化、规范化、便利化，优化流程，实现当日申请受理，提高效率。 在涉外仲裁领域，依托苏州自贸片区国际商事仲裁院，增聘涉外仲裁员，加强境外合作，邀请专家 举办讲座并提供法律咨询，助力企业应对贸易壁垒；针对民企知识产权保护，组建专业仲裁员队伍，优 化维权方式，打造便捷渠道。 苏州仲裁委还探索"仲裁+调解"模式，深化仲调对接，丰富纠纷解决路径；主动参与民企依法依规 管理，组织仲裁员服务团 ...

随后，美国法院批准了申请人的临时禁令申请，要求被申请人不得处置其财产。被申请人虽抗辩称仲裁 庭对争议借款的金额统计有误，仲裁裁决违反公共政策而不具有可执行性。但美国法院驳回了被申请人 的论点，并认为其没有提供任何证据说明仲裁庭得出了错误的结论、也没有证明这样的错误可能达到违 反公共政策的程度。据此，认为本案仲裁程序不存在违反《纽约公约》情况，支持了申请人关于承认和 执行该仲裁裁决的申请。本案体现了仲裁"跨境执行"的优势和便利，为仲裁裁决的最终执行提供坚实保 障，让当事人的合法权益得以切实维护。 据统计，2024年，深圳国际仲裁院新受理商事仲裁案件14518宗，涉及争议金额1422.67亿元，在已公布 的仲裁机构中继续位列世界前列；与此同时，涉外商事仲裁案件增至520宗，争议金额合计510.39亿 元。案件当事人来自64个国家和地区，同比上升45%，当事人累计覆盖国家和地区增至142个，覆盖地 域进一步扩大。 （文章来源：深圳商报） 【深圳商报讯】（记者范宏韬）5月14日，记者从深圳国际仲裁院（华南国际经济贸易仲裁委员会、粤 港澳大湾区国际仲裁中心，简称SCIA）了解到，近期SCIA多宗仲裁裁决依据《联合国承认 ...

Financial Data and Key Metrics Changes - The company reported revenue of $1,360,000,000 for the quarter, reflecting a 3% organic growth year over year [6][30] - Adjusted EBITDA margin was 13.7%, in the upper end of the near-term guidance range [6][30] - Adjusted EPS was $2.01, compared to $1.57 for the prior year period [30][42] Business Line Data and Key Metrics Changes - U.S. Federal Services segment revenue increased by 10.9% to $778,000,000, driven by strong clinical assessments [33] - U.S. Services segment revenue decreased to $442,000,000, reflecting normalization after last year's Medicaid unwinding [35] - Outside the U.S. segment revenue decreased to $142,000,000, but organic growth was 4.6% [36] Market Data and Key Metrics Changes - The total pipeline of sales opportunities was $41,200,000,000, with approximately 55% representing new work [26] - Signed awards totaled $2,900,000,000 of total contract value through the second quarter [25] - The book to bill ratio was approximately 0.8 times, showing improvement from previous periods [26] Company Strategy and Development Direction - The company is focused on leveraging technology and innovation to drive efficient operations and enhance customer satisfaction [8][12] - MAXIMUS FORWARD initiatives aim to modernize programs through technology and performance-based contracting [7][8] - The company is exploring opportunities for efficiencies and innovation in response to government inquiries [13][14] Management's Comments on Operating Environment and Future Outlook - Management maintains a cautious view for the second half of the fiscal year due to evolving operating conditions [14][42] - The company anticipates a normalization in cash flow and collections in the fourth quarter [38][43] - There is optimism regarding the pipeline of opportunities, with an uptick in business proposals volume [29][30] Other Important Information - The company has been recognized by Fortune as one of America's most innovative companies, highlighting its commitment to operational innovation [27] - Cash provided by operating activities was $43,000,000, with free cash flow of $26,000,000 for the quarter [37] - The company ended the quarter with total debt of $1,510,000,000, yielding a net leverage ratio of 1.9 times [41] Q&A Session Summary Question: How should the market think about the guidance and weightings between Q3 and Q4? - Management indicated that the guidance reflects Q2 overperformance while maintaining a cautious approach for Q3 and Q4 due to visibility into potential moderation in clinical volumes [51][52] Question: Can you provide more color on the margin performance in the quarter? - The strong margin performance was attributed to increased volumes and investments in technology that improved operational efficiencies [55][56] Question: Are there potential delays in new work coming into the pipeline? - There has been some slowdown in the civilian agency space, but the company is still seeing opportunities and contract extensions that benefit incumbents [60][62] Question: What are the drivers behind the organic growth in the Outside the U.S. segment? - The organic growth was primarily driven by the functional assessment services contract in the UK, which provides a modest revenue increase compared to the predecessor contract [67]

Financial Data and Key Metrics Changes - The company reported revenue of $1,360,000,000 for the quarter, representing a solid 3% organic growth year over year [5][25] - Adjusted EBITDA margin was 13.7% in Q2, in the upper end of the near-term guidance range [5][25] - Adjusted EPS was $2.01 for the quarter, compared to $1.57 for the prior year period [25][28] Business Line Data and Key Metrics Changes - U.S. Federal Services segment revenue increased 10.9% to $778,000,000, all organic growth, driven by strong performance in clinical assessments [28] - U.S. Services segment revenue decreased to $442,000,000, reflecting the prior year's outsized growth from Medicaid unwinding [29] - Outside the U.S. segment revenue decreased to $142,000,000, but organic growth was 4.6% due to healthier components remaining [30] Market Data and Key Metrics Changes - The total pipeline of sales opportunities was $41,200,000,000, with approximately 55% representing new work [22][23] - Signed awards totaled $2,900,000,000 of total contract value through the second quarter [21] - The book to bill ratio was approximately 0.8 times, showing improvement from previous periods [22] Company Strategy and Development Direction - The company is focused on modernization through technology and performance-based contracting, aligning with government efficiency initiatives [6][10] - MAXIMUS FORWARD transformation emphasizes technology and innovation to drive efficient operations and customer satisfaction [7][10] - The company is exploring opportunities for efficiencies, consolidation, and innovation in response to government inquiries [11][12] Management's Comments on Operating Environment and Future Outlook - Management maintains a cautious view for the second half of the fiscal year, reflecting ongoing uncertainties in the operating environment [12][36] - The company anticipates a normalization in cash flow and collections in the fourth quarter, following delays in administrative processes [32][36] - There is optimism regarding the pipeline of opportunities, with an uptick in business proposals volume [25][56] Other Important Information - The company has been recognized by Fortune as one of America's most innovative companies, highlighting its commitment to operational innovation and technology [23] - Cash provided by operating activities was $43,000,000, with free cash flow of $26,000,000 for the quarter [31] - Total debt at the end of the quarter was $1,510,000,000, yielding a net total leverage ratio of 1.9 times [35] Q&A Session Summary Question: How should the market think about the guidance and weightings between Q3 and Q4? - Management indicated that the guidance reflects Q2 overperformance while maintaining a cautious approach for Q3 and Q4 due to visibility into potential moderation in clinical volumes [44][46] Question: Can you provide more color on the margin performance drivers? - The strong margin performance was attributed to increased volumes and investments in technology that improved operational efficiency [49][50] Question: Are there potential delays in new work coming into the pipeline? - There has been some slowdown in the civilian agency space, but the overall pipeline volume remains healthy, with a 25% increase in proposals in preparation [53][54]